Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults by Graff M et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is published under a Creative Commons CC0 1.0 Universal public domain dedication 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Graff M, Scott RA, Justice AE, et al  
Genome-wide physical activity interactions in adiposity - A meta-analysis of 
200,452 adults.  
PLoS Genetics 2017, 13(4), e1006528. 
 
 
Copyright: 
This is an open access article, free of all copyright, and may be freely reproduced, distributed, 
transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made 
available under the Creative Commons CC0 public domain dedication. 
DOI link to article: 
https://doi.org/10.1371/journal.pgen.1006528  
Date deposited:   
02/06/2017 
RESEARCH ARTICLE
Genome-wide physical activity interactions in
adiposity ― A meta-analysis of 200,452 adults
Mariaelisa Graff1☯*, Robert A. Scott2☯, Anne E. Justice1☯, Kristin L. Young1,3☯, Mary
F. Feitosa4, Llilda Barata4, Thomas W. Winkler5, Audrey Y. Chu6,7, Anubha Mahajan8,
David Hadley9, Luting Xue6,10, Tsegaselassie Workalemahu11, Nancy L. Heard-Costa6,12,
Marcel den Hoed2,13, Tarunveer S. Ahluwalia14,15, Qibin Qi16, Julius S. Ngwa17,
Frida Renstro¨m18,19, Lydia Quaye20, John D. Eicher21, James E. Hayes22,23,
Marilyn Cornelis11,24,25, Zoltan Kutalik26,27, Elise Lim10, Jian’an Luan2, Jennifer
E. Huffman6,28, Weihua Zhang29,30, Wei Zhao31, Paula J. Griffin10, Toomas Haller32,
Shafqat Ahmad18, Pedro M. Marques-Vidal33, Stephanie Bien34, Loic Yengo35,
Alexander Teumer36,37, Albert Vernon Smith38,39, Meena Kumari40, Marie
Neergaard Harder14, Johanne Marie Justesen14, Marcus E. Kleber41,42, Mette Hollensted14,
Kurt Lohman43, Natalia V. Rivera44, John B. Whitfield45, Jing Hua Zhao2, Heather
M. Stringham46, Leo-Pekka Lyytika¨inen47,48, Charlotte Huppertz49,50,51,
Gonneke Willemsen49,50, Wouter J. Peyrot52, Ying Wu53, Kati Kristiansson54,55,
Ayse Demirkan56,57, Myriam Fornage58,59, Maija Hassinen60, Lawrence F. Bielak31,
Gemma Cadby61, Toshiko Tanaka62, Reedik Ma¨gi32, Peter J. van der Most63, Anne
U. Jackson46, Jennifer L. Bragg-Gresham46, Veronique Vitart28, Jonathan Marten28,
Pau Navarro28, Claire Bellis64,65, Dorota Pasko66, Åsa Johansson67, Søren Snitker68, Yu-
Ching Cheng68,69, Joel Eriksson70, Unhee Lim71, Mette Aadahl72,73, Linda S. Adair74,
Najaf Amin56, Beverley Balkau75, Juha Auvinen76,77, John Beilby78,79,80, Richard
N. Bergman81, Sven Bergmann27,82, Alain G. Bertoni83,84, John Blangero85,
Ame´lie Bonnefond35, Lori L. Bonnycastle86, Judith B. Borja87,88, Søren Brage2,
Fabio Busonero89, Steve Buyske90,91, Harry Campbell92, Peter S. Chines86, Francis
S. Collins86, Tanguy Corre27,82, George Davey Smith93, Graciela E. Delgado41,
Nicole Dueker94, Marcus Do¨rr37,95, Tapani Ebeling96,97, Gudny Eiriksdottir38,
Tõnu Esko32,98,99,100, Jessica D. Faul101, Mao Fu68, Kristine Færch15,
Christian Gieger102,103,104, Sven Gla¨ser95, Jian Gong34, Penny Gordon-Larsen3,74,
Harald Grallert102,104,105, Tanja B. Grammer41, Niels Grarup14, Gerard van Grootheest52,
Kennet Harald54, Nicholas D. Hastie28, Aki S. Havulinna54, Dena Hernandez106,
Lucia Hindorff107, Lynne J. Hocking108,109, Oddgeir L. Holmens110,
Christina Holzapfel102,111, Jouke Jan Hottenga49,112, Jie Huang113, Tao Huang11,
Jennie Hui78,79,114, Cornelia Huth104,105, Nina Hutri-Ka¨ho¨nen115,116, Alan L. James78,117,118,
John-Olov Jansson119, Min A. Jhun31, Markus Juonala120,121, Leena Kinnunen122, Heikki
A. Koistinen122,123,124, Ivana Kolcic125, Pirjo Komulainen60, Johanna Kuusisto126,
Kirsti Kvaløy127, Mika Ka¨ho¨nen128,129, Timo A. Lakka60,130, Lenore J. Launer131,
Benjamin Lehne29, Cecilia M. Lindgren8,132,133, Mattias Lorentzon70,134, Robert Luben135,
Michel Marre136,137, Yuri Milaneschi52, Keri L. Monda1,138, Grant W. Montgomery45,
Marleen H. M. De Moor50,139, Antonella Mulas89,140, Martina Mu¨ller-Nurasyid103,141,142, A.
W. Musk78,114,143, Reija Ma¨nnikko¨60, Satu Ma¨nnisto¨54, Narisu Narisu86,
Matthias Nauck37,144, Jennifer A. Nettleton59, Ilja M. Nolte63, Albertine J. Oldehinkel145,
Matthias Olden5, Ken K. Ong2, Sandosh Padmanabhan109,146, Lavinia Paternoster93,
Jeremiah Perez10, Markus Perola54,55,147, Annette Peters104,105,142, Ulrike Peters34, Patricia
A. Peyser31, Inga Prokopenko148, Hannu Puolijoki149, Olli T. Raitakari150,151,
Tuomo Rankinen152, Laura J. Rasmussen-Torvik24, Rajesh Rawal102,103,104, Paul
M. Ridker7,153, Lynda M. Rose7, Igor Rudan92, Cinzia Sarti154, Mark A. Sarzynski152,
Kai Savonen60, William R. Scott29, Serena Sanna89, Alan R. Shuldiner68,69,
Steve Sidney155, Gu¨nther Silbernagel156, Blair H. Smith109,157, Jennifer A. Smith31,
Harold Snieder63, Alena Stanča´kova´126, Barbara Sternfeld155, Amy J. Swift86,
Tuija Tammelin158, Sian-Tsung Tan159, Barbara Thorand104,105, Dorothe´e Thuillier35,
Liesbeth Vandenput70, Henrik Vestergaard14,15, Jana V. van Vliet-Ostaptchouk160,
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006528 April 27, 2017 1 / 26
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Graff M, Scott RA, Justice AE, Young KL,
Feitosa MF, Barata L, et al. (2017) Genome-wide
physical activity interactions in adiposity ― A meta-
analysis of 200,452 adults. PLoS Genet 13(4):
e1006528. https://doi.org/10.1371/journal.
pgen.1006528
Editor: Todd L. Edwards, Vanderbilt University,
UNITED STATES
Received: August 17, 2016
Accepted: December 7, 2016
Published: April 27, 2017
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: All genome-wide
association meta-analysis results files are available
at the GIANT Consortium website: www.
broadinstitute.org/collaboration/giant.
Funding: The views expressed in this manuscript
are those of the authors and do not necessarily
represent the views of the National Heart, Lung,
and Blood Institute; the National Institutes of
Health; or the U.S. Department of Health and
Human Services. Funding for this study was
provided by the Aase and Ejner Danielsens
Marie-Claude Vohl161,162, Uwe Vo¨lker37,163, Ge´rard Waeber33, Mark Walker164,
Sarah Wild165, Andrew Wong166, Alan F. Wright28, M. Carola Zillikens167, Niha Zubair34,
Christopher A. Haiman168, Loic Lemarchand71, Ulf Gyllensten67, Claes Ohlsson70,
Albert Hofman169,170, Fernando Rivadeneira167,169,170, Andre´ G. Uitterlinden167,169,
Louis Pe´russe161,171, James F. Wilson28,92, Caroline Hayward28, Ozren Polasek92,125,
Francesco Cucca89,140, Kristian Hveem127, Catharina A. Hartman172, Anke To¨njes173,
Stefania Bandinelli174, Lyle J. Palmer175, Sharon L. R. Kardia31, Rainer Rauramaa60,176,
Thorkild I. A. Sørensen14,73,93,177, Jaakko Tuomilehto122,178,179, Veikko Salomaa54, Brenda
W. J. H. Penninx52, Eco J. C. de Geus49,50, Dorret I. Boomsma49,112, Terho Lehtima¨ki47,48,
Massimo Mangino20,180, Markku Laakso126, Claude Bouchard152, Nicholas G. Martin45,
Diana Kuh166, Yongmei Liu83, Allan Linneberg72,181,182, Winfried Ma¨rz41,183,184,
Konstantin Strauch103,185, Mika Kivima¨ki186, Tamara B. Harris187,
Vilmundur Gudnason38,39, Henry Vo¨lzke36,37, Lu Qi11, Marjo-Riitta Ja¨rvelin29,76,77,188,189,
John C. Chambers29,30,190, Jaspal S. Kooner30,159,190, Philippe Froguel35,191,
Charles Kooperberg34, Peter Vollenweider33, Go¨ran Hallmans19, Torben Hansen14,
Oluf Pedersen14, Andres Metspalu32, Nicholas J. Wareham2, Claudia Langenberg2, David
R. Weir101, David J. Porteous109,192, Eric Boerwinkle59, Daniel I. Chasman7,100,153, CHARGE
Consortium, EPIC-InterAct Consortium, PAGE Consortium¶, Gonc¸alo R. Abecasis46,
Inês Barroso193,194,195, Mark I. McCarthy8,196,197, Timothy M. Frayling66, Jeffrey
R. O’Connell68, Cornelia M. van Duijn56,170,198, Michael Boehnke46, Iris M. Heid5, Karen
L. Mohlke53, David P. Strachan199, Caroline S. Fox21, Ching-Ti Liu10, Joel
N. Hirschhorn99,100,200, Robert J. Klein23, Andrew D. Johnson6,21, Ingrid B. Borecki4, Paul
W. Franks11,18,201, Kari E. North202, L. Adrienne Cupples6,10, Ruth J. F. Loos2,203,204,205‡*,
Tuomas O. Kilpela¨inen2,14,205‡*
1 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel
Hill, Chapel Hill, North Carolina, United States of America, 2 MRC Epidemiology Unit, Institute of Metabolic
Science, University of Cambridge, Cambridge, United Kingdom, 3 Carolina Population Center, University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 4 Department of
Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America,
5 Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany, 6 National Heart,
Lung, and Blood Institute, Framingham Heart Study, Framingham, Massachusetts, United States of America,
7 Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of
America, 8 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom,
9 Division of Population Health Sciences and Education, St. George’s, University of London, London, United
Kingdom, 10 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts,
United States of America, 11 Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston,
Massachusetts, United States of America, 12 Department of Neurology, Boston University School of
Medicine, Boston, Massachusetts, United States of America, 13 Department of Immunology, Genetics and
Pathology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, 14 Novo Nordisk
Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and
Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 15 Steno Diabetes Center, Gentofte,
Denmark, 16 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx,
New York, United States of America, 17 Howard University, Department of Internal Medicine, Washington
DC, United States of America, 18 Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit,
Lund University, Malmo¨, Sweden, 19 Department of Biobank Research, UmeåUniversity, Umeå, Sweden,
20 Department of Twin Research and Genetic Epidemiology, King’s College London, London, United
Kingdom, 21 Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of
Health, The Framingham Heart Study, Framingham, Massachusetts, United States of America, 22 Cell and
Developmental Biology Graduate Program, Weill Cornell Graduate School of Medical Sciences, Cornell
University, New York, New York, United States of America, 23 Icahn Institute for Genomics and Multiscale
Biology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America,
24 Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago,
Illinois, United States of America, 25 Channing Division of Network Medicine, Department of Medicine,
Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of
America, 26 Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne,
Switzerland, 27 Swiss Institute of Bioinformatics, Lausanne, Switzerland, 28 MRC Human Genetics Unit,
Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh,
United Kingdom, 29 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College
London, London, United Kingdom, 30 Department of Cardiology, Ealing Hospital HNS Trust, Middlesex,
United Kingdom, 31 Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor,
Genome-wide physical activity interactions in adiposity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006528 April 27, 2017 2 / 26
Foundation; Academy of Finland (102318; 104781,
120315, 123885, 129619, 286284, 134309,
126925, 121584, 124282, 129378, 117787,
250207, 258753, 41071, 77299, 124243,
1114194, 24300796); Accare Center for Child and
Adolescent Psychiatry; Action on Hearing Loss
(G51); Agence Nationale de la Recherche; Agency
for Health Care Policy Research (HS06516); Age
UK Research into Ageing Fund; Åke Wiberg
Foundation; ALF/LUA Research Grant in
Gothenburg; ALFEDIAM; ALK-Abello´ A/S
(Hørsholm, Denmark); American Heart Association
(13POST16500011, 10SDG269004); Ardix
Medical; Arthritis Research UK; Association
Diabète Risque Vasculaire; AstraZeneca; Australian
Associated Brewers; Australian National Health and
Medical Research Council (241944, 339462,
389927, 389875, 389891, 389892, 389938,
442915, 442981, 496739, 552485, 552498); Avera
Research Institute; Bayer Diagnostics; Becton
Dickinson; Biobanking and Biomolecular
Resources Research Infrastructure (BBMRI –NL,
184.021.007); Biocentrum Helsinki; Boston Obesity
Nutrition Research Center (DK46200); British Heart
Foundation (RG/10/12/28456, SP/04/002); Canada
Foundation for Innovation; Canadian Institutes of
Health Research (FRN-CCT-83028); Cancer
Research UK; Cardionics; Center for Medical
Systems Biology; Center of Excellence in Complex
Disease Genetics and SALVECenter of Excellence in
Genomics (EXCEGEN); Chief Scientist Office of the
Scottish Government; City of Kuopio; Cohortes
Sante´ TGIR; Contrat de Projets E´tat-Re´gion;
Croatian Science Foundation (8875); Danish
Agency for Science, Technology and Innovation;
Danish Council for Independent Research (DFF–
1333-00124, DFF–1331-007308); Danish Diabetes
Academy; Danish Medical Research Council;
Department of Psychology and Education of the VU
University Amsterdam; Diabetes Hilfs- und
Forschungsfonds Deutschland; Dutch Brain
Foundation; Dutch Ministry of Justice; Emil
Aaltonen Foundation; Erasmus Medical Center;
Erasmus University; Estonian Government (IUT20-
60, IUT24-6); Estonian Ministry of Education and
Research (3.2.0304.11-0312); European
Commission (230374, 284167, 323195, 692145,
FP7 EurHEALTHAgeing-277849, FP7 BBMRI-LPC
313010, nr 602633, HEALTH-F2-2008-201865-
GEFOS, HEALTH-F4-2007-201413, FP6 LSHM-CT-
2004-005272, FP5 QLG2-CT-2002-01254, FP6
LSHG-CT-2006-01947, FP7 HEALTH-F4-2007-
201413, FP7 279143, FP7 201668, FP7 305739,
FP6 LSHG-CT-2006-018947, HEALTH-F4-2007-
201413, QLG1-CT-2001-01252); European
Regional Development Fund; European Science
Foundation (EuroSTRESS project FP-006, ESF, EU/
Michigan, United States of America, 32 Estonian Genome Center, University of Tartu, Tartu, Estonia,
33 Department of Internal Medicine, Internal Medicine, Lausanne University Hospital, Lausanne,
Switzerland, 34 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle,
Washington, United States of America, 35 University of Lille, CNRS, Institut Pasteur de Lille, UMR 8199 -
EGID, Lille, France, 36 Institute for Community Medicine, University Medicine Greifswald, Greifswald,
Germany, 37 DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald,
Germany, 38 Icelandic Heart Association, Kopavogur, Iceland, 39 Faculty of Medicine, University of Iceland,
Reykjavik, Iceland, 40 ISER, University of Essex, Colchester, Essex, United Kingdom, 41 Vth Department of
Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, 42 Institute of Nutrition,
Friedrich Schiller University Jena, Jena, Germany, 43 Department of Biostatistical Sciences, Division of
Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of
America, 44 Karolinska Institutet, Respiratory Unit, Department of Medicine Solna, Stockholm, Sweden,
45 Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia, 46 Center for
Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, United States
of America, 47 Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland, 48 Department of
Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland, 49 Department of Biological
Psychology, Vrije Universiteit, Amsterdam, The Netherlands, 50 EMGO+ Institute, Vrije Universiteit & VU
University Medical Center, Amsterdam, The Netherlands, 51 Department of Public and Occupational Health,
VU University Medical Center, Amsterdam, The Netherlands, 52 Department of Psychiatry, EMGO Institute
for Health and Care Research and Neuroscience Campus Amsterdam, VU University Medical Center/GGZ
InGeest, Amsterdam, The Netherlands, 53 Department of Genetics, University of North Carolina, Chapel Hill,
North Carolina, United States of America, 54 National Institute for Health and Welfare, Department of Health,
Helsinki, Finland, 55 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland,
56 Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands,
57 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands, 58 Institute
of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States
of America, 59 Division of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas
Health Science Center at Houston, Houston, Texas, United States of America, 60 Kuopio Research Institute
of Exercise Medicine, Kuopio, Finland, 61 Centre for Genetic Origins of Health and Disease, University of
Western Australia, Crawley, Western Australia, Australia, 62 Translational Gerontology Branch, National
Institute on Aging, Baltimore, Maryland, United States of America, 63 Department of Epidemiology,
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 64 Human
Genetics, Genome Institute of Singapore, Agency for Science, Technology and Research of Singapore,
Singapore, 65 Genomics Research Centre, Institute of Health and Biomedical Innovation, Queensland
University of Technology, Brisbane, Queensland, Australia, 66 Genetics of Complex Traits, University of
Exeter Medical School, University of Exeter, Exeter, United Kingdom, 67 Department of Immunology,
Genetics and Pathology, Uppsala University, Uppsala, Sweden, 68 Division of Endocrinology, Diabetes, and
Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, United States of America,
69 Veterans Affairs Maryland Health Care System, University of Maryland, Baltimore, Maryland, United
States of America, 70 Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical
Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,
71 Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America,
72 Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark,
73 Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark, 74 Department of Nutrition, Gillings School of Global Public Health, University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 75 INSERM U-1018,
CESP, Renal and Cardiovascular Epidemiology, UVSQ-UPS, Villejuif, France, 76 Center for Life Course
Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland, 77 Unit of Primary Care, Oulu
University Hospital, Oulu, Finland, 78 Busselton Population Medical Research Institute, Nedlands, Western
Australia, Australia, 79 PathWest Laboratory Medicine of WA, Sir Charles Gairdner Hospital, Nedlands,
Western Australia, Australia, 80 School of Pathology and Laboratory Medicine, The University of Western
Australia, Crawley, Western Australia, Australia, 81 Diabetes and Obesity Research Institute, Cedars-Sinai
Medical Center, Los Angeles, California, United States of America, 82 Department of Medical Genetics,
University of Lausanne, Lausanne, Switzerland, 83 Department of Epidemiology and Prevention, Division of
Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of
America, 84 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North
Carolina, United States of America, 85 Texas Biomedical Research Institute, San Antonio, Texas, United
States of America, 86 Medical Genomics and Metabolic Genetics Branch, National Human Genome
Research Institute, NIH, Bethesda, Maryland, United States of America, 87 USC-Office of Population Studies
Foundation, Inc., University of San Carlos, Cebu City, Philippines, 88 Department of Nutrition and Dietetics,
University of San Carlos, Cebu City, Philippines, 89 Istituto di Ricerca Genetica e Biomedica (IRGB),
Consiglio Nazionale Delle Ricerche (CNR), Cittadella Universitaria di Monserrato, Monserrato, Italy,
90 Department of Genetics, Rutgers University, Piscataway, New Jersey, United States of America,
Genome-wide physical activity interactions in adiposity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006528 April 27, 2017 3 / 26
QLRT-2001-01254); Faculty of Biology and
Medicine of Lausanne; Federal Ministry of
Education and Research (01ZZ9603, 01ZZ0103,
01ZZ0403, 03ZIK012, 03IS2061A); Federal State of
Mecklenburg - West Pomerania; Fe´de´ration
Franc¸aise de Cardiologie; Finnish Cultural
Foundation; Finnish Diabetes Association; Finnish
Foundation of Cardiovascular Research; Finnish
Heart Association; Food Standards Agency;
Fondation de France; Fonds Sante´; Genetic
Association Information Network of the Foundation
for the National Institutes of Health; German
Diabetes Association; German Federal Ministry of
Education and Research (BMBF, 01ER1206,
01ER1507); German Research Council (SFB-1052,
SPP 1629 TO 718/2-1); GlaxoSmithKline; Go¨ran
Gustafssons Foundation; Go¨teborg Medical
Society; Health and Safety Executive; Heart
Foundation of Northern Sweden; Icelandic Heart
Association; Icelandic Parliament; Imperial College
Healthcare NHS Trust; INSERM, Re´seaux en Sante´
Publique, Interactions entre les de´terminants de la
sante´; Interreg IV Oberrhein Program (A28); Italian
Ministry of Economy and Finance; Italian Ministry
of Health (ICS110.1/RF97.71); John D and
Catherine T MacArthur Foundation; Juho Vainio
Foundation; King’s College London; Kjell och Ma¨rta
Beijers Foundation; Kuopio University Hospital;
Kuopio, Tampere and Turku University Hospital
Medical Funds (X51001); Leiden University
Medical Center; Lilly; LMUinnovativ; Lundbeck
Foundation; Lundberg Foundation; Medical
Research Council of Canada; MEKOS Laboratories
(Denmark); Merck Sante´; Mid-Atlantic Nutrition
Obesity Research Center (P30 DK72488);
Ministère de l’E´conomie, de l’Innovation et des
Exportations; Ministry for Health, Welfare and
Sports of the Netherlands; Ministry of Cultural
Affairs of the Federal State of Mecklenburg-West
Pomerania; Ministry of Education and Culture of
Finland (627;2004-2011); Ministry of Education,
Culture and Science of the Netherlands; MRC
Human Genetics Unit; MRC-GlaxoSmithKline Pilot
Programme Grant (G0701863); Municipality of
Rotterdam; Netherlands Bioinformatics Centre
(2008.024); Netherlands Consortium for Healthy
Aging (050-060-810); Netherlands Genomics
Initiative; Netherlands Organisation for Health
Research and Development (904-61-090, 985-10-
002, 904-61-193, 480-04-004, 400-05-717,
Addiction-31160008, Middelgroot-911-09-032,
Spinozapremie 56-464-14192); Netherlands
Organisation for Health Research and Development
(2010/31471/ZONMW); Netherlands Organisation
for Scientific Research (10-000-1002, GB-MW
940-38-011, 100-001-004, 60-60600-97-118, 261-
98-710, GB-MaGW 480-01-006, GB-MaGW 480-
91 Department of Statistics and Biostatistics, Rutgers University, Piscataway, New Jersey, United States of
America, 92 Centre for Global Health Research, Usher Institute for Population Health Sciences and
Informatics, Edinburgh, Scotland, 93 MRC Integrative Epidemiology Unit & School of Social and Community
Medicine, University of Bristol, Bristol, United Kingdom, 94 University of Maryland School of Medicine,
Department of Epidemiology & Public Health, Baltimore, Maryland, United States of America, 95 Department
of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany, 96 Department of Medicine,
Oulu University Hospital, Oulu, Finland, 97 Institute of Clinical Medicine, Faculty of Medicine, University of
Oulu, Oulu, Finland, 98 Division of Endocrinology, Boston Children’s Hospital, Boston, Massachusetts,
United States of America, 99 Department of Genetics, Harvard Medical School, Boston, Massachusetts,
United States of America, 100 Broad Institute of the Massachusetts Institute of Technology and Harvard
University, Cambridge, Massachusetts, United States of America, 101 Survey Research Center, Institute for
Social Research, University of Michigan, Ann Arbor, Michigan, United States of America, 102 Research Unit
of Molecular Epidemiology, Helmholtz Zentrum Mu¨nchen - German Research Center for Environmental
Health, Neuherberg, Germany, 103 Institute of Genetic Epidemiology, Helmholtz Zentrum Mu¨nchen, German
Research Center for Environmental Health, Neuherberg, Germany, 104 Institute of Epidemiology II,
Helmholtz Zentrum Mu¨nchen-German Research Center for Environmental Health, Neuherberg, Germany,
105 German Center for Diabetes Research (DZD), Mu¨nchen-Neuherberg, Germany, 106 Laboratory of
Neurogenetics, National Institute on Aging, Bethesda, Maryland, United States of America, 107 Division of
Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda,
Maryland, United States of America, 108 Musculoskeletal Research Programme, Division of Applied
Medicine, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom, 109 Generation Scotland, Centre
for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, United Kingdom, 110 St. Olav
Hospital, Trondheim University Hospital, Trondheim, Norway, 111 Institute for Nutritional Medicine, Klinikum
Rechts der Isar, Technische Universita¨t Mu¨nchen, Munich, Germany, 112 NCA Institute, VU University & VU
Medical Center, Amsterdam, The Netherlands, 113 Department of Human Genetics, Wellcome Trust Sanger
Institute, Hinxton, Cambridge, United Kingdom, 114 School of Population Health, The University of Western
Australia, Crawley, Western Australia, Australia, 115 Department of Pediatrics, Tampere University Hospital,
Tampere, Finland, 116 Department of Pediatrics, University of Tampere School of Medicine, Tampere,
Finland, 117 Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital,
Nedlands, Western Australia, Australia, 118 School of Medicine and Pharmacology, The University of
Western Australia, Crawley, Western Australia, Australia, 119 Department of Physiology, Institute of
Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,
120 Department of Medicine, University of Turku, Turku, Finland, 121 Division of Medicine, Turku University
Hospital, Turku, Finland, 122 National Institute for Health and Welfare, Department of Health, Helsinki,
Finland, 123 Department of Medicine and Abdominal Center: Endocrinology, University of Helsinki and
Helsinki University Central Hospital, Helsinki, Finland, 124 Minerva Foundation Institute for Medical
Research, Helsinki, Finland, 125 Department of Public Health, Faculty of Medicine, University of Split, Split,
Croatia, 126 Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio,
Finland, 127 HUNT Research Centre, Department of Public Health and General Practice, Norwegian
University of Science and Technology, Levanger, Norway, 128 Department of Clinical Physiology, Tampere
University Hospital, Tampere, Finland, 129 Department of Clinical Physiology, University of Tampere School
of Medicine, Tampere, Finland, 130 Institute of Biomedicine, Physiology, University of Eastern Finland,
Kuopio Campus, Finland, 131 Neuroepidemiology Section, National Institute on Aging, National Institutes of
Health, Bethesda, Maryland, United States of America, 132 Program in Medical and Population Genetics,
Broad Institute, Cambridge, Massachusetts, United States of America, 133 The Big Data Institute, University
of Oxford, Oxford, United Kingdom, 134 Geriatric Medicine, Sahlgrenska University Hospital, Mo¨lndal,
Sweden, 135 Department of Public Health and Primary Care, University of Cambridge, Cambridge, United
Kingdom, 136 INSERM U-1138, E´ quipe 2: Pathophysiology and Therapeutics of Vascular and Renal
diseases Related to Diabetes, Centre de Recherche des Cordeliers, Paris, France, 137 Department of
Endocrinology, Diabetology, Nutrition, and Metabolic Diseases, Bichat Claude Bernard Hospital, Paris,
France, 138 Center for Observational Research, Amgen Inc., Thousand Oaks, California, United States of
America, 139 Section of Clinical Child and Family Studies, Department of Educational and Family Studies,
Vrije Universiteit, Amsterdam, The Netherlands, 140 Dipartimento di Scienze Biomediche, Università degli
Studi di Sassari, Sassari, Italy, 141 Department of Medicine I, Ludwig-Maximilians-Universita¨t, Munich,
Germany, 142 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance,
Munich, Germany, 143 Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands,
Western Australia, Australia, 144 Institute of Clinical Chemistry and Laboratory Medicine, University Medicine
Greifswald, Greifswald, Germany, 145 Interdisciplinary Center Psychopathology and Emotion Regulation
(ICPE), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands,
146 Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre,
University of Glasgow, Glasgow, United Kingdom, 147 University of Tartu, Estonian Genome Centre, Tartu,
Estonia, 148 Genomics of Common Disease, Imperial College London, London, United Kingdom, 149 South
Ostrobothnia Central Hospital, Seina¨joki, Finland, 150 Department of Clinical Physiology and Nuclear
Genome-wide physical activity interactions in adiposity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006528 April 27, 2017 4 / 26
07-001, GB-MaGW 452-04-314, GB-MaGW 452-
06-004, 175.010.2003.005, 175.010.2005.011,
481-08-013, 480-05-003, 911-03-012);
Neuroscience Campus Amsterdam; NHS
Foundation Trust; Novartis Pharmaceuticals; Novo
Nordisk; Office National Interprofessionel des Vins;
Paavo Nurmi Foundation; Påhlssons Foundation;
Pa¨ivikki and Sakari Sohlberg Foundation; Pierre
Fabre; Republic of Croatia Ministry of Science,
Education and Sport (108-1080315-0302);
Research Centre for Prevention and Health, the
Capital Region for Denmark; Research Institute for
Diseases in the Elderly (014-93-015, RIDE2);
Roche; Russian Foundation for Basic Research
(NWO-RFBR 047.017.043); Rutgers University Cell
and DNA Repository (NIMH U24 MH068457-06);
Sanofi-Aventis; Scottish Executive Health
Department (CZD/16/6); Siemens Healthcare;
Social Insurance Institution of Finland (4/26/2010);
Social Ministry of the Federal State of
Mecklenburg-West Pomerania; Socie´te´
Francophone du Diabète; State of Bavaria; Stroke
Association; Swedish Diabetes Association;
Swedish Foundation for Strategic Research;
Swedish Heart-Lung Foundation (20140543);
Swedish Research Council (2015-03657); Swedish
Medical Research Council (K2007-66X-20270-01-
3, 2011-2354); Swedish Society for Medical
Research; Swiss National Science Foundation
(33CSCO-122661, 33CS30-139468, 33CS30-
148401); Tampere Tuberculosis Foundation; The
Marcus Borgstro¨m Foundation; The Royal Society;
The Wellcome Trust (084723/Z/08/Z, 088869/B/09/
Z); Timber Merchant Vilhelm Bangs Foundation;
Topcon; Torsten and Ragnar So¨derberg’s
Foundation; UK Department of Health; UK Diabetes
Association; UK Medical Research Council
(MC_U106179471, G0500539, G0600705,
G0601966, G0700931, G1002319, K013351,
MC_UU_12019/1); UK National Institute for Health
Research BioResource Clinical Research Facility
and Biomedical Research Centre; UK National
Institute for Health Research (NIHR)
Comprehensive Biomedical Research Centre; UK
National Institute for Health Research (RP-PG-
0407-10371); UmeåUniversity Career
Development Award; United States – Israel
Binational Science Foundation Grant (2011036);
University Hospital Oulu (75617); University
Medical Center Groningen; University of Tartu
(SP1GVARENG); National Institutes of Health
(AG13196, CA047988, HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C,
HHSC271201100004C, HHSN268200900041C,
HHSN268201300025C, HHSN268201300026C,
HHSN268201300027C, HHSN268201300028C,
Medicine, Turku University Hospital, Turku, Finland, 151 Research Centre of Applied and Preventive
Cardiovascular Medicine, University of Turku, Turku, Finland, 152 Human Genomics Laboratory, Pennington
Biomedical Research Center, Baton Rouge, Louisiana, United States of America, 153 Harvard Medical
School, Boston, Massachusetts, United States of America, 154 Social Services and Health Care Department,
City of Helsinki, Helsinki, Finland, 155 Division of Research, Kaiser Permanente Northern California,
Oakland, California, United States of America, 156 Division of Angiology, Department of Internal Medicine,
Medical University Graz, Austria, 157 School of Medicine, University of Dundee, Ninewells Hospital and
Medical School, Dundee, Scotland, 158 LIKES Research Center for Sport and Health Sciences, Jyva¨skyla¨,
Finland, 159 National Heart and Lung Institute, Imperial College London, United Kingdom, 160 Department
of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The
Netherlands, 161 Institute of Nutrition and Functional Foods, Quebec, Canada, 162 School of Nutrition, Laval
University, Quebec, Canada, 163 Interfaculty Institute for Genetics and Functional Genomics, University
Medicine Greifswald, Germany, 164 Institute of Cellular Medicine, Newcastle University, Newcastle upon
Tyne, United Kingdom, 165 Centre for Population Health Sciences, Usher Institute for Population Health
Sciences and Informatics, Teviot Place, Edinburgh, Scotland, 166 MRC Unit for Lifelong Health and Ageing
at UCL, London, United Kingdom, 167 Department of Internal Medicine, Erasmus MC, Rotterdam, The
Netherlands, 168 Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of
Medicine, University of Southern California, Los Angeles, California, United States of America,
169 Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands, 170 Netherlands Consortium
for Healthy Aging, Leiden University Medical Center, Leiden, The Netherlands, 171 Department of
Kinesiology, Laval University, Quebec, Canada, 172 Department of Psychiatry, University of Groningen,
University Medical Center Groningen, Groningen, The Netherlands, 173 University of Leipzig, Medical
Department, Leipzig, Germany, 174 Geriatric Unit, Azienda Sanitaria Firenze, Florence, Italy, 175 School of
Public Health, University of Adelaide, Adelaide, South Australia, Australia, 176 Department of Clinical
Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland, 177 Department of Clinical
Epidemiology, Bispebjerg and Frederiksberg Hospitals, The Capital Region, Copenhagen, Denmark,
178 Centre for Vascular Prevention, Danube-University Krems, Krems, Austria, 179 Diabetes Research
Group, King Abdulaziz University, Jeddah, Saudi Arabia, 180 National Institute for Health Research
Biomedical Research Centre at Guy’s and St. Thomas’ Foundation Trust, London, United Kingdom,
181 Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark, 182 Department of
Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
Denmark, 183 Synlab Academy, Synlab Services LLC, Mannheim, Germany, 184 Clinical Institute of
Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria, 185 Institute of
Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-
Universita¨t, Munich, Germany, 186 Department of Epidemiology and Public Health, University College
London, London, United Kingdom, 187 Laboratory of Epidemiology and Population Science, National
Institute on Aging, Bethesda, Maryland, United States of America, 188 Biocenter Oulu, University of Oulu,
Oulu, Finland, 189 MRC-PHE Centre for Environment and Health, Imperial College London, London, United
Kingdom, 190 Imperial College Healthcare NHS Trust, London, United Kingdom, 191 Hammersmith
Hospital, London, United Kingdom, 192 Centre for Genomic and Experimental Medicine, Institute of Genetics
and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom, 193 Wellcome Trust Sanger
Institute, Hinxton, United Kingdom, 194 NIHR Cambridge Biomedical Research Centre, Institute of Metabolic
Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, 195 The University of Cambridge Metabolic
Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom,
196 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital,
Oxford, United Kingdom, 197 Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom,
198 Center of Medical Systems Biology, Leiden, The Netherlands, 199 Population Health Research Institute,
St. George’s University of London, London, United Kingdom, 200 Divisions of Endocrinology and Genetics
and Center for Basic and Translational Obesity Research, Boston Children’s Hospital, Boston,
Massachusetts, United States of America, 201 Department of Public Health & Clinical Medicine, Umeå
University, Umeå, Sweden, 202 Carolina Center for Genome Sciences, Gillings School of Global Public
Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America,
203 Genetics of Obesity and Related Metabolic Traits Program, Charles Bronfman Institute for Personalized
Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America, 204 The
Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New
York, United States of America, 205 The Department of Preventive Medicine, The Icahn School of Medicine
at Mount Sinai, New York, New York, United States of America
☯ These authors contributed equally to this work.
‡ These authors jointly supervised this work.
¶ Membership is listed in the Supporting Information.
* migraff@email.unc.edu (MG); ruth.loos@mssm.edu (RJFL); tuomas.kilpelainen@sund.ku.dk (TOK)
Genome-wide physical activity interactions in adiposity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006528 April 27, 2017 5 / 26
HHSN268201300029C, HHSN268201500001I,
HL36310, HG002651, HL034594, HL054457,
HL054481, HL071981, HL084729, HL119443,
HL126024, N01-AG12100, N01-AG12109, N01-
HC25195, N01-HC55015, N01-HC55016, N01-
HC55018, N01-HC55019, N01-HC55020, N01-
HC55021, N01-HC55022, N01-HD95159, N01-
HD95160, N01-HD95161, N01-HD95162, N01-
HD95163, N01-HD95164, N01-HD95165, N01-
HD95166, N01-HD95167, N01-HD95168, N01-
HD95169, N01-HG65403, N02-HL64278, R01-
HD057194, R01-HL087641, R01-HL59367,
R01HL-086694, R01-HL088451, R24-HD050924,
U01-HG-004402, HHSN268200625226C, UL1-
RR025005, UL1-RR025005, UL1-TR-001079,
UL1-TR-00040, AA07535, AA10248, AA11998,
AA13320, AA13321, AA13326, AA14041,
AA17688, DA12854, MH081802, MH66206, R01-
D004215701A, R01-DK075787, R01-DK089256,
R01-DK8925601, R01-HL088451, R01-HL117078,
R01-DK062370, R01-DK072193, DK091718,
DK100383, DK078616, 1Z01-HG000024,
HL087660, HL100245, R01DK089256,
2T32HL007055-36, U01-HL072515-06, U01-
HL84756, NIA-U01AG009740, RC2-AG036495,
RC4-AG039029, R03 AG046389, 263-MA-410953,
263-MD-9164, 263-MD-821336, U01-HG004802,
R37CA54281, R01CA63, P01CA33619, U01-
CA136792, U01-CA98758, RC2-MH089951,
MH085520, R01-D0042157-01A, MH081802,
1RC2-MH089951, 1RC2-MH089995,
1RL1MH08326801, U01-HG007376, 5R01-
HL08767902, 5R01MH63706:02, HG004790, N01-
WH22110, U01-HG007033, UM1CA182913,
24152, 32100-2, 32105-6, 32108-9, 32111-13,
32115, 32118-32119, 32122, 42107-26, 42129-
32, 44221); USDA National Institute of Food and
Agriculture (2007-35205-17883); Va¨stra Go¨taland
Foundation; Velux Foundation; Veterans Affairs (1
IK2 BX001823); Vleugels Foundation; VU
University’s Institute for Health and Care Research
(EMGO+, HEALTH-F4-2007-201413) and
Neuroscience Campus Amsterdam; Wellcome
Trust (090532, 091551, 098051, 098381);
Wissenschaftsoffensive TMO; and Yrjo¨ Jahnsson
Foundation. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: We have read the journal’s
policy and the authors of this manuscript have the
following competing interests: Genotyping in the
Ely and Fenland studies was supported in part by
an MRC-GlaxoSmithKline pilot programme grant
(G0701863). The RISC Study was supported in
part by AstraZeneca. The D.E.S.I.R. study has been
supported in part by INSERM contracts with Lilly,
Novartis Pharma, Sanofi-Aventis, Ardix Medical,
Abstract
Physical activity (PA) may modify the genetic effects that give rise to increased risk of obe-
sity. To identify adiposity loci whose effects are modified by PA, we performed genome-
wide interaction meta-analyses of BMI and BMI-adjusted waist circumference and waist-hip
ratio from up to 200,452 adults of European (n = 180,423) or other ancestry (n = 20,029).
We standardized PA by categorizing it into a dichotomous variable where, on average, 23%
of participants were categorized as inactive and 77% as physically active. While we replicate
the interaction with PA for the strongest known obesity-risk locus in the FTO gene, of which
the effect is attenuated by ~30% in physically active individuals compared to inactive individ-
uals, we do not identify additional loci that are sensitive to PA. In additional genome-wide
meta-analyses adjusting for PA and interaction with PA, we identify 11 novel adiposity loci,
suggesting that accounting for PA or other environmental factors that contribute to variation
in adiposity may facilitate gene discovery.
Author summary
Decline in daily physical activity is thought to be a key contributor to the global obesity
epidemic. However, the impact of sedentariness on adiposity may be in part determined
by a person’s genetic constitution. The specific genetic variants that are sensitive to physi-
cal activity and regulate adiposity remain largely unknown. Here, we aimed to identify
genetic variants whose effects on adiposity are modified by physical activity by examining
~2.5 million genetic variants in up to 200,452 individuals. We also tested whether adjust-
ing for physical activity as a covariate could lead to the identification of novel adiposity
variants. We find robust evidence of interaction with physical activity for the strongest
known obesity risk-locus in the FTO gene, of which the body mass index-increasing effect
is attenuated by ~30% in physically active individuals compared to inactive individuals.
Our analyses indicate that other similar gene-physical activity interactions may exist, but
better measurement of physical activity, larger sample sizes, and/or improved analytical
methods will be required to identify them. Adjusting for physical activity, we identify 11
novel adiposity variants, suggesting that accounting for physical activity or other environ-
mental factors that contribute to variation in adiposity may facilitate gene discovery.
Introduction
In recent decades, we have witnessed a global obesity epidemic that may be driven by changes
in lifestyle such as easier access to energy-dense foods and decreased physical activity (PA) [1].
However, not everyone becomes obese in obesogenic environments. Twin studies suggest that
changes in body weight in response to lifestyle interventions are in part determined by a per-
son’s genetic constitution [2–4]. Nevertheless, the genes that are sensitive to environmental
influences remain largely unknown.
Previous studies suggest that genetic susceptibility to obesity, assessed by a genetic risk
score for BMI, may be attenuated by PA [5, 6]. A large-scale meta-analysis of the FTO obesity
locus in 218,166 adults showed that being physically active attenuates the BMI-increasing
effect of this locus by ~30% [7]. While these findings suggest that FTO, and potentially other
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previously established BMI loci, may interact with PA, it has been hypothesized that loci show-
ing the strongest main effect associations in genome-wide association studies (GWAS) may be
the least sensitive to environmental and lifestyle influences, and may therefore not make the
best candidates for interactions [8]. Yet no genome-wide search for novel loci exhibiting
SNP×PA interaction has been performed. A genome-wide meta-analysis of genotype-depen-
dent phenotypic variance of BMI, a marker of sensitivity to environmental exposures, in
~170,000 participants identified FTO, but did not show robust evidence of environmental sen-
sitivity for other loci [9]. Recent genome-wide meta-analyses of adiposity traits in>320,000
individuals uncovered loci interacting with age and sex, but also suggested that very large sam-
ple sizes are required for interaction studies to be successful [10].
Here, we report results from a large-scale genome-wide meta-analysis of SNP×PA interac-
tions in adiposity in up to 200,452 adults. As part of these interaction analyses, we also examine
whether adjusting for PA or jointly testing for SNP’s main effect and interaction with PA may
identify novel adiposity loci.
Results
Identification of loci interacting with PA
We performed meta-analyses of results from 60 studies, including up to 180,423 adults of
European descent and 20,029 adults of other ancestries to assess interactions between ~2.5 mil-
lion genotyped or HapMap-imputed SNPs and PA on BMI and BMI-adjusted waist circumfer-
ence (WCadjBMI) and waist-hip ratio (WHRadjBMI) (S1–S5 Tables). Similar to a previous meta-
analysis of the interaction between FTO and PA [7], we standardized PA by categorizing it
into a dichotomous variable where on average ~23% of participants were categorized as inac-
tive and ~77% as physically active (see Methods and S6 Table). On average, inactive individu-
als had 0.99 kg/m2 higher BMI, 3.46 cm higher WC, and 0.018 higher WHR than active
individuals (S4 and S5 Tables).
Each study first performed genome-wide association analyses for each SNP’s effect on BMI
in the inactive and active groups separately. Corresponding summary statistics from each
cohort were subsequently meta-analyzed, and the SNP×PA interaction effect was estimated by
calculating the difference in the SNP’s effect between the inactive and active groups. To iden-
tify sex-specific SNP×PA interactions, we performed the meta-analyses separately in men and
women, as well as in the combined sample. In addition, we carried out meta-analyses in Euro-
pean-ancestry studies only and in European and other-ancestry studies combined.
We used two approaches to identify loci whose effects are modified by PA. In the first
approach, we searched for genome-wide significant SNP×PA interaction effects (PINT<5x10-8).
As shown in Fig 1, this approach yielded the highest power to identify cross-over interaction
effects where the SNP’s effect is directionally opposite between the inactive and active groups.
However, this approach has low power to identify interaction effects where the SNP’s effect is
directionally concordant between the inactive and active groups (Fig 1). We identified a
genome-wide significant interaction between rs986732 in cadherin 12 (CDH12) and PA on
BMI in European-ancestry studies (betaINT = -0.076 SD/allele, PINT = 3.1x10
-8, n = 134,767) (S7
Table). The interaction effect was directionally consistent but did not replicate in an indepen-
dent sample of 31,097 individuals (betaINT = -0.019 SD/allele, PINT = 0.52), and the pooled asso-
ciation P value for the discovery and replication stages combined did not reach genome-wide
significance (NTOTAL = 165,864; PINT-TOTAL = 3x10
-7) (S1 Fig). No loci showed genome-wide
significant interactions with PA on WCadjBMI or WHRadjBMI. CDH12 encodes an integral mem-
brane protein mediating calcium-dependent cell-cell adhesion in the brain, where it may play a
role in neurogenesis [11]. While CDH12 rs4701252 and rs268972 SNPs have shown suggestive
Genome-wide physical activity interactions in adiposity
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Fig 1. Power to identify PA-adjusted main, joint or GxPA interaction effects in 200,000 individuals (45,000 inactive, 155,000 active). The
plots compare power to identify genome-wide significant main effects (PadjPA<5x10-8, dashed black), joint effects (PJOINT<5x10-8, dotted green)
or GxPA interaction effects (PINT<5x10-8, solid magenta) as well as the power to identify Bonferroni-corrected interaction effects (PINT<0.05/
number of loci, solid orange) for the SNPs that reached a genome-wide significant PA-adjusted main effect association (PadjPA<5x10-8). The
power computations were based on analytical power formulae provided elsewhere [50] and were conducted a-priori based on various types of
Genome-wide physical activity interactions in adiposity
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associations with waist circumference (P = 2x10-6) and BMI (P = 5x10-5) in previous GWAS
[12, 13], the SNPs are not in LD with rs986732 (r2<0.1).
In our second approach, we tested interaction for loci showing a genome-wide significant
main effect on BMI, WCadjBMI or WHRadjBMI (S7–S12 Tables). We adjusted the significance
threshold for SNP×PA interaction by Bonferroni correction (P = 0.05/number of SNPs tested).
As shown in Fig 1, this approach enhanced our power to identify interaction effects where
there is a difference in the magnitude of the SNP’s effect between inactive and active groups
when the SNP’s effect is directionally concordant between the groups. We identified a signifi-
cant SNP×PA interaction of the FTO rs9941349 SNP on BMI in the meta-analysis of Euro-
pean-ancestry individuals; the BMI-increasing effect was 33% smaller in active individuals
(betaACTIVE = 0.072 SD/allele) than in inactive individuals (betaINACTIVE = 0.106 SD/allele,
PINT = 4x10
-5). The rs9941349 SNP is in strong LD (r2 = 0.87) with FTO rs9939609 for which
interaction with PA has been previously established in a meta-analysis of 218,166 adults [7].
We identified no loci interacting with PA for WCadjBMI or WHRadjBMI.
In a previously published meta-analysis [7], the FTO locus showed a geographic difference
for the interaction effect where the interaction was more pronounced in studies from North
America than in those from Europe. To test for geographic differences in the present study, we
performed additional meta-analyses for the FTO rs9941349 SNP, stratified by geographic ori-
gin (North America vs. Europe). While the interaction effect was more pronounced in studies
from North America (betaINT = 0.052 SD/allele, P = 5x10
-4, N = 63,896) than in those from
Europe (betaINT = 0.028 SD/allele, P = 0.006, N = 109,806), we did not find a statistically signif-
icant difference between the regions (P = 0.14).
Explained phenotypic variance in inactive and active individuals. We tested whether
the variance explained by ~1.1 million common variants (MAF1%) differed between the
inactive and active groups for BMI, WCadjBMI, and WHRadjBMI [14]. In the physically active
individuals, the variants explained ~20% less of variance in BMI than in inactive individuals
(12.4% vs. 15.7%, respectively; Pdifference = 0.046), suggesting that PA may reduce the impact of
genetic predisposition to adiposity overall. There was no significant difference in the variance
explained between active and inactive groups for WCadjBMI (8.6% for active, 9.3% for inactive;
Pdifference = 0.70) or WHRadjBMI (6.9% for active, 8.0% for inactive; Pdifference = 0.59).
To further investigate differences in explained variance between the inactive and active
groups, we calculated variance explained by subsets of SNPs selected based on significance
thresholds (ranging from P = 5x10-8 to P = 0.05) of PA-adjusted SNP association with BMI,
WCadjBMI or WHRadjBMI [15] (S13 Table). We found 17–26% smaller explained variance for
BMI in the active group than in the inactive group at all P value thresholds (S13 Table).
Identification of novel loci when adjusting for PA or when jointly testing
for SNP main effect and interaction with PA
Physical activity contributes to variation in BMI, WCadjBMI, and WHRadjBMI, hence, adjusting
for PA as a covariate may enhance power to identify novel adiposity loci. To that extent, each
study performed genome-wide analyses for association with BMI, WCadjBMI, and WHRadjBMI
while adjusting for PA. Subsequently, we performed meta-analyses of the study-specific
known realistic BMI effect sizes [51]. Panels A, C, E: Assuming an effect in inactive individuals similar to a small (R2INACT ¼ 0:01%, comparable to
the known BMI effect of the NUDT3 locus), medium (R2INACT ¼ 0:07%, comparable to the known BMI effect of the BDNF locus) and large
(R2INACT ¼ 0:34%, comparable to the known BMI effect of the FTO locus) realistic effect on BMI and for various effects in physically active
individuals (varied on the x axis); Panels B,D,F: Assuming an effect in physically active individuals similar to the small, medium and large realistic
effects of the NUDT3, BDNF and FTO loci on BMI and for various effects in inactive individuals (varied on x axis).
https://doi.org/10.1371/journal.pgen.1006528.g001
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results. We discovered 10 genome-wide significant loci (2 for BMI, 1 for WCadjBMI, 7 for
WHRadjBMI) that have not been reported in previous GWAS of adiposity traits (Table 1, S2–S4
Figs).
To establish whether additionally accounting for SNP×PA interactions would identify
novel loci, we calculated the joint significance of PA-adjusted SNP main effect and SNP×PA
interaction using the method of Aschard et al [16]. As illustrated in Fig 1, the joint test
enhanced our power to identify loci where the SNP shows simultaneously a main effect and an
interaction effect. We identified a novel BMI locus near ELAVL2 in men (PJOINT = 4x10-8),
which also showed suggestive evidence of interaction with PA (PINT = 9x10
-4); the effect of the
BMI-increasing allele was attenuated by 71% in active as compared to inactive individuals
(betaINACTIVE = 0.087 SD/allele, betaACTIVE = 0.025 SD/allele) (Table 1, S2–S4 Figs).
To evaluate the effect of PA adjustment on the results for the 11 novel loci, we performed a
look-up in published GIANT consortium meta-analyses for BMI, WCadjBMI, and WHRadjBMI
that did not adjust for PA [17, 18] (S22 Table). All 11 loci showed a consistent direction of
effect between the present PA-adjusted and the previously published PA-unadjusted results,
but the PA-unadjusted associations were less pronounced despite up to 40% greater sample
size, suggesting that adjustment for PA may have increased our power to identify these loci.
The biological relevance of putative candidate genes in the novel loci, based on our thor-
ough searches of the literature, GWAS catalog look-ups, and analyses of eQTL enrichment and
overlap with functional regulatory elements, are described in Tables 2 and 3. As the novel loci
were identified in a PA-adjusted model, where adjusting for PA may have contributed to their
identification, we examined whether the lead SNPs in these loci are associated with the level of
PA. More specifically, we performed look-ups in GWAS analyses for the levels of moderate-to-
vigorous intensity leisure-time PA (n = 80,035), TV-viewing time (n = 28,752), and sedentary
behavior at work (n = 59,381) or during transportation (n = 15,152) [personal communication
with Marcel den Hoed, Marilyn Cornelis, and Ruth Loos]. However, we did not find signifi-
cant associations when correcting for the number of loci that were examined (P>0.005) (S16
Table).
Identification of secondary signals
In addition to uncovering 11 novel adiposity loci, our PA-adjusted GWAS and the joint test of
SNP main effect and SNP×PA interaction confirmed 148 genome-wide significant loci (50 for
BMI, 58 for WCadjBMI, 40 for WHRadjBMI) that have been established in previous main effect
GWAS for adiposity traits (S7–S12 Tables, S4 Fig). The lead SNPs in eight of the previously
established loci (5 for BMI, 3 for WCadjBMI), however, showed no LD or only weak LD
(r2<0.3) with the published lead SNP, suggesting they could represent novel secondary signals
in known loci (S17 Table). To test whether these eight signals are independent of the previ-
ously published signals, we performed conditional analyses [19]. Three of the eight SNPs we
examined, in/near NDUFS4,MEF2C-AS1 and CPA1, were associated with WCadjBMI with
P<5x10-8 in our PA-adjusted GWAS even after conditioning on the published lead SNP,
hence representing novel secondary signals in these loci (S17 Table).
Enrichment of the identified loci with functional regulatory elements
Epigenetic variation may underlie gene-environment interactions observed in epidemiological
studies [20] and PA has been shown to induce marked epigenetic changes in the genome [21].
We examined whether the BMI or WHRadjBMI loci reaching P<1x10
-5 for interaction with PA
(13 loci for BMI, 5 for WHRadjBMI) show overall enrichment with chromatin states in adipose,
brain and muscle tissues available from the Roadmap Epigenomics Consortium [22].
Genome-wide physical activity interactions in adiposity
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However, we did not find significant enrichment (S18 and S19 Tables), which may be due to
the limited number of identified loci. The lack of significant findings may also be due to the
assessment of chromatin states in the basal state, which may not reflect the dynamic changes
that occur when cells are perturbed by PA [23].
We also tested whether the loci reaching P<5x10-8 in our PA-adjusted GWAS of BMI or
WHRadjBMI show enrichment with chromatin states and found significant enrichment of the
BMI loci with enhancer, weak transcription, and polycomb-repressive elements in several
brain cell lines, and with enhancer elements in three muscle cell lines (S20 and S21 Tables).
We also found significant enrichment of the WHRadjBMI loci with enhancer elements in
three adipose and six muscle cell lines, with active transcription start sites in two adipose cell
lines, and with polycomb-repressive elements in seven brain cell lines. The enrichment of
our PA-adjusted main effect results with chromatin annotations in skeletal muscle in partic-
ular, the tissue most affected by PA, could highlight regulatory mechanisms that may be
influenced by PA.
Discussion
In this genome-wide meta-analysis of more than 200,000 adults, we do not find evidence of
interaction with PA for loci other than the established FTO locus. However, when adjusting
for PA or jointly testing for SNP main effect and interaction with PA, we identify 11 novel adi-
posity loci, suggesting that accounting for PA or other environmental factors that contribute
to variation in adiposity may increase power for gene discovery.
Our results suggest that if SNP×PA interaction effects for common variants exist, they are
unlikely to be of greater magnitude than observed for FTO, the BMI-increasing effect of
which is attenuated by ~30% in physically active individuals. The fact that common SNPs
Table 2. Genes of biological interest within 500 kb of lead SNPs associated with BMI.
CCK (rs754635): The lead SNP is located in intron 1 of the CCK gene that encodes cholecystokinin, a
gastrointestinal peptide that stimulates the digestion of fat and protein in the small intestine by inhibiting
gastric emptying, inducing the release of pancreatic enzymes, increasing production of hepatic bile, and
causing contraction of the gallbladder. Cholecystokinin induces satiety and reduces the amount of food
consumed when administered prior to a meal [52, 53]. In a candidate gene study, four common variants in
CCK were associated with increased meal size [54], but the variants are not in LD with rs754635 (r2<0.1). A
GWAS of BMI in 62,246 individuals of East Asian ancestry showed a suggestive association (P = 2x10-7) for
the rs4377469 SNP in high LD with our lead SNP (r2 = 0.7) [55].
ELAVL2 (rs1934100): The lead SNP showed an association with BMI only in men (Table 1). The only
nearby gene ELAVL2 (455 kb away) is a conserved neuron-specific RNA-binding protein involved in
stabilization or enhanced translation of specific mRNAs with AU-rich elements in the 3’-untranslated region
[56]. While ELAVL2 is implicated in neuronal differentiation [56], potential mechanisms linking this function
to obesity remain unclear.
MRAS (rs1720825): The lead SNP is an intronic variant in MRAS. The MRAS rs1199333 SNP, in high LD
with rs1720825 (r2 = 0.85), has shown suggestive association with typical sporadic amyotrophic lateral
sclerosis in a Chinese Han population (P = 4x10-6, S14 Table). Other MRAS SNPs have been associated
with risk of coronary artery disease [57] but they are not in LD with rs1720825 (r2<0.06). MRAS encodes a
member of the membrane-associated Ras small GTPase protein family that function as signal transducers
in multiple processes of cell growth and differentiation and are involved in energy expenditure,
adipogenesis, muscle differentiation, insulin signaling and glucose metabolism [58–60]. Mice with Mras
knockout develop a severe obesity phenotype [61]. The SNP rs1199334, in high LD with our lead SNP
rs1720825 (r2 = 0.90), has been identified as the SNP most strongly associated with the cis-expression of
centrosomal protein 70kDa (CEP70) in subcutaneous adipose tissue (P = 2x10-7) (S15 Table). CEP70
encodes a centrosomal protein that is critical for the regulation of mitotic spindle assembly, playing an
essential role in cell cycle progression [62].
https://doi.org/10.1371/journal.pgen.1006528.t002
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Table 3. Genes of biological interest within 500 kb of lead SNPs associated with WCadjBMI or
WHRadjBMI.
ZSCAN2 (rs7176527): Twenty two genes lie within 500kb of the WCadjBMI-associated lead SNP (S3 Fig).
The nearest gene, ZSCAN2, contains several copies of a zinc finger motif commonly found in
transcriptional regulatory proteins. The rs7176527 SNP is in LD (r2>0.80) with five SNPs (rs3762168,
rs2762169, rs12594450, rs72630460, and rs16974951) that are enhancers in multiple tissues in the data
from Roadmap Epigenomics Consortium [22]. The rs7176527 SNP is a cis-eQTL for the putative
transcriptional regulator SCAND2 [63] in the intestine, prefrontal cortex, and lymphocytes (S15 Table).
PAPPA2 (rs4650943): Seven genes lie within 500kb of the lead SNP (S3 Fig). The nearest gene, PAPPA2,
is 18 kb upstream of rs4650943 and codes for a protease that locally regulates insulin-like growth factor
availability through cleavage of IGF binding protein 5, most commonly found in bone tissue. In murine
models, the PAPP-A2 protein has been shown to influence overall body size and bone growth, but not
glucose metabolism or adiposity [64–66].
MEIS1 (rs2300481): The only gene within 500 kb of the lead SNP is MEIS1 encoding a homeobox protein
that plays an important role in normal organismal growth and development. Two variants in high LD with the
lead SNP (r2 = 0.95) have been identified for association with PR interval of the heart (S14 Table). Another
variant, in low LD with rs2300481 (r2 = 0.25), has been associated with restless leg syndrome [67]–a
sleeping disorder that may cause weight gain [68].
ARHGEF28 (rs167025): The lead SNP showed an association with WHRadjBMI in men only (Table 1).
There are two protein-coding genes within 500kb of rs167025. The nearest gene is ARHGEF28, 195 kb
downstream, encoding Rho guanine nucleotide exchange factor 28. This exchange factor has been shown
to destabilize low molecular weight neurofilament mRNAs in patients with amyotrophic lateral sclerosis,
leading to degeneration and death of motor neurons controlling voluntary muscle movement [69, 70]. The
ENC1 gene, 490 kb away, encodes Ectoderm-neural cortex protein 1, an actin-binding protein required for
adipocyte differentiation [71]
HCP5 (rs3094013): The lead SNP showed an association with WHRadjBMI in men only (Table 1). The
rs3094013 SNP is located in the MHC complex on chromosome 6, and the region within 500kb contains
124 genes (S3 Fig). The known WHRadjBMI-increasing allele rs3099844, in strong LD with our lead SNP
(r20.8), has previously been associated with increased HDL-cholesterol levels [72]. Candidate gene
studies suggest that rs1800629 in tumor necrosis factor (TNF), which is 109 kb upstream and in moderate
LD (r2 = 0.64) with the lead SNP, may interact with physical activity to decrease serum CRP levels [73, 74].
We did not, however, find an interaction between rs1800629 and physical activity on WHRadjBMI (P = 0.3).
BAZ1B (rs6976930): There are 31 genes within 500kb the lead SNP rs6976930 (S3 Fig) which is in high
LD (r2>0.8) with GWAS hits associated with protein C levels, triglycerides, serum urate levels, lipid
metabolism, metabolic syndrome, and gamma-glutamyl transferase levels (S14 Table). The rs6976930
SNP shows an eQTL association with MLXIPL expression in omental (P = 7x10-22) and subcutaneous
adipose tissue (P = 4x10-14). MLXIPL is 122 kb downstream of rs6976930 and codes for a transcription
factor that binds carbohydrate response motifs, increasing transcription of genes involved in glycolysis,
lipogenesis, and triglyceride synthesis [75, 76].
PLCE1 (rs10786152): There are 8 genes within 500 kb of the lead SNP (S3 Fig). The lead SNP lies within
the intron of PLCE1 encoding a phospholipase involved in cellular growth and differentiation and gene
expression among many other biological processes involving phospholipids [77]. Variants in this gene have
been shown to cause nephrotic syndrome, type 3 [78]. Nearby variants rs9663362 and rs932764 (r2 = 1.0
and 0.85, respectively) have been previously associated with systolic and diastolic blood pressure (S14
Table).
CTRB2 (rs889512): The lead SNP showed an association with WHRadjBMI in women only (Table 1). There
are 17 genes within 500 kb (S3 Fig). The nearby rs4888378 SNP has been associated with carotid intima-
media thickness in women but not in men, and BCAR1 (breast cancer anti-estrogen resistance protein 1)
has been implicated as the causal gene [79]. The rs488378 SNP is not, however, in LD with our lead SNP
(r2<0.1). The SNP rs7202877, in moderate LD with rs889512 (r2 = 0.6), is a risk variant for type 1 diabetes
(S14 Table). The data from Roadmap Epigenomics Consortium [22] suggest that five variants in strong LD
(r2>0.8) with our lead SNP rest in known regulatory regions, including rs9936550 within an active enhancer
region and rs72802352 in a DNAse hypersensitive region for human skeletal muscle cells and myoblasts;
and rs147630228 and rs111869668 within active enhancer regions for the pancreas. Additionally,
rs111869668 rests within binding motifs for CEBPB and CEBPD (CCAAT enhancer-binding protein-Beta
and Delta) which are enhancer proteins involved in adipogenesis [80, 81].
https://doi.org/10.1371/journal.pgen.1006528.t003
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explain less of the BMI variance among physically active compared to inactive individuals
indicates that further interactions may exist, but larger meta-analyses, more accurate and
precise measurement of PA, and/or improved analytical methods will be required to identify
them. We found no difference between inactive and active individuals in variance explained
by common SNPs in aggregate for WCadjBMI or WHRadjBMI, and no loci interacted with PA
on WCadjBMI or WHRadjBMI. Therefore, PA may not modify genetic influences as strongly
for body fat distribution as for overall adiposity. Furthermore, while differences in variance
explained by common variants may be due to genetic effects being modified by PA, it is
important to note that heritability can change in the absence of changes in genetic effects, if
environmental variation differs between the inactive and active groups. Therefore, the lower
BMI variance explained in the active group could be partly due to a potentially greater envi-
ronmental variation in this group.
While we replicated the previously observed interaction between FTO and PA [7], it
remains unclear what biological mechanisms underlie the attenuation in FTO’s effect in physi-
cally active individuals, and whether the interaction is due to PA or due to confounding by
other environmental exposures. While some studies suggest that FTO may interact with diet
[24–26], a recent meta-analysis of 177,330 individuals did not find interaction between FTO
and dietary intakes of total energy, protein, carbohydrate or fat [27]. The obesity-associated
FTO variants are located in a super-enhancer region [28] and have been associated with DNA
methylation levels [29–31], suggesting that this region may be sensitive to epigenetic effects
that could mediate the interaction between FTO and PA.
In genome-wide analyses for SNP main effects adjusting for PA, or when testing for the
joint significance of SNP main effect and SNPxPA interaction, we identify 11 novel adiposity
loci, even though our sample size was up to 40% smaller than in the largest published main
effect meta-analyses [17, 18]. Our findings suggest that accounting for PA may facilitate the
discovery of novel adiposity loci. Similarly, accounting for other environmental factors that
contribute to variation in adiposity could lead to the discovery of additional loci.
In the present meta-analyses, statistical power to identify SNPxPA interactions may have
been limited due to challenges relating to the measurement and statistical modeling of PA [5].
Of the 60 participating studies, 56 assessed PA by self-report while 4 used wearable PA moni-
tors. Measurement error and bias inherent in self-report estimates of PA [32] can attenuate
effect sizes for SNP×PA interaction effects towards the null [33]. Measurement using PA mon-
itors provides more consistent results, but the monitors are not able to cover all types of activi-
ties and the measurement covers a limited time span compared to questionnaires [34]. As
sample size requirements increase nonlinearly when effect sizes decrease, any factor that leads
to a deflation in the observed interaction effect estimates may make their detection very diffi-
cult, even when very large population samples are available for analysis. Finally, because of the
wide differences in PA assessment tools used among the participating studies, we treated PA as
a dichotomous variable, harmonizing PA into inactive and active individuals. Considerable
loss of power is anticipated when a continuous PA variable is dichotomized [35]. Our power
could be enhanced by using a continuous PA variable if a few larger studies with equivalent,
quantitative PA measurements were available.
In summary, while our results suggest that adjusting for PA or other environmental factors
that contribute to variation in adiposity may increase power for gene discovery, we do not find
evidence of SNP×PA interaction effects stronger than that observed for FTO. While other
SNP×PA interaction effects on adiposity are likely to exist, combining many small studies with
varying characteristics and PA assessment tools may be inefficient for identifying such effects
[5]. Access to large cohorts with quantitative, equivalent PA variables, measured with relatively
high accuracy and precision, may be necessary to uncover novel SNP×PA interactions.
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Methods
Main analyses
Ethics statement. All studies were conducted according to the Declaration of Helsinki.
The studies were approved by the local ethical review boards and all study participants pro-
vided written informed consent for the collection of samples and subsequent analyses.
Outcome traits—BMI, WCadjBMI and WHRadjBMI. We examined three anthropometric
traits related to overall adiposity (BMI) or body fat distribution (WCadjBMI and WHRadjBMI)
[36] that were available from a large number of studies. Before the association analyses, we cal-
culated sex-specific residuals by adjusting for age, age2, BMI (for WCadjBMI and WHRadjBMI
traits only), and other necessary study-specific covariates, such as genotype-derived principal
components. Subsequently, we normalized the distributions of sex-specific trait residuals
using inverse normal transformation.
Physical activity. Physical activity was assessed and quantified in various ways in the par-
ticipating studies of the meta-analysis (S1 and S6 Tables). Aiming to amass as large a sample
size as possible, we harmonized PA by categorizing it into a simple dichotomous variable—
physically inactive vs. active—that could be derived in a relatively consistent way in all partici-
pating studies, and that would be consistent with previous findings on gene-physical activity
interactions and the relationship between activity levels and health outcomes. In studies with
categorical PA data, individuals were defined inactive if they reported having a sedentary occu-
pation and being sedentary during transport and leisure-time (<1 h of moderate intensity lei-
sure-time or commuting PA per week). All other individuals were defined physically active.
Previous studies in large-scale individual cohorts have demonstrated that the interaction
between FTO, or a BMI-increasing genetic risk score, with physical activity, is most pro-
nounced approximately at this activity level [6, 37, 38]. In studies with continuous PA data,
PA variables were standardized by defining individuals belonging to the lowest sex- and age-
adjusted quintile of PA levels as inactive, and all other individuals as active. The study-specific
coding of the dichotomous PA variable in each study is described in S6 Table.
Study-specific association analyses. We included 42 studies with genome-wide data, 10
studies with Metabochip data, and eight studies with both genome-wide and Metabochip data.
If both genome-wide and Metabochip data were available for the same individual, we only
included the genome-wide data (S1 Table). Studies with genome-wide genotyped data used
either Affymetrix or Illumina arrays (S2 Table). Following study-specific quality control mea-
sures, the genotype data were imputed using the HapMap phase II reference panel (S2 Table).
Studies with Metabochip data used the custom Illumina HumanCardio-Metabo BeadChip
containing ~195K SNPs designed to support large-scale follow-up of known associations with
metabolic and cardiovascular traits [39]. Each study ran autosomal SNP association analyses
with BMI, WCadjBMI and WHRadjBMI across their array of genetic data using the following lin-
ear regression models in men and women separately: 1) active individuals only; 2) inactive
individuals only; and 3) active and inactive individuals combined, adjusting for the PA stra-
tum. In studies that included families or closely related individuals, regression coefficients
were estimated using a variance component model that modeled relatedness in men and
women combined, with sex as a covariate, in addition to the sex-specific analyses. The additive
genetic effect for each SNP and phenotype association was estimated using linear regression.
For studies with a case-control design (S1 Table), cases and controls were analyzed separately.
Quality control of study-specific association results. All study-specific files for the three
regression models listed above were processed through a standardized quality control protocol
using the EasyQC software [40]. The study-specific quality control measures included checks
on file completeness, range of test statistics, allele frequencies, trait transformation, population
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stratification, and filtering out of low quality data. Checks on file completeness included
screening for missing alleles, effect estimates, allele frequencies, and other missing data.
Checks on range of test statistics included screening for invalid statistics such as P-values >1
or<0, negative standard errors, or SNPs with low minor allele count (MAC, calculated as
MAFN, where MAF is the minor allele frequency and N is the sample size) and where SNPs
with MAC<5 in the inactive or the active group were removed. The correctness of trait trans-
formation to inverse normal was examined by plotting 2/median of the standard error with
the square root of the sample size. Population stratification was examined by calculating the
study specific genomic control inflation factor (λGC) [41]. If a study had λGC>1.1, the study
analyst was contacted and asked to revise the analyses by adjusting for principal components.
The allele frequencies in each study were examined for strand issues and miscoded alleles by
plotting effect allele frequencies against the corresponding allele frequencies from the Hap-
Map2 reference panel. Finally, low quality data were filtered out by removing monomorphic
SNPs, imputed SNPs with poor imputation quality (r2_hat <0.3 in MACH [42], observed/
expected dosage variance <0.3 in BIMBAM [43], proper_info <0.4 in IMPUTE [44]), and
genotyped SNPs with a low call-rate (<95%) or that were out of Hardy-Weinberg equilibrium
(P<10−6).
Meta-analyses. Beta-coefficients and standard errors were combined by an inverse-vari-
ance weighted fixed effect method, implemented using the METAL software [45]. We per-
formed meta-analyses for each of the three models (active, inactive, active + inactive adjusted
for PA) in men only, in women only, and in men and women combined. Study-specific
GWAS results were corrected for genomic control using all SNPs. Study-specific Metabochip
results as well as the meta-analysis results for GWAS and Metabochip combined were cor-
rected for genomic control using 4,425 SNPs included on the Metabochip for replication of
associations with QT-interval, a phenotype not correlated with BMI, WCadjBMI or WHRadjBMI,
after pruning of SNPs within 500 kb of an anthropometry replication SNP. We excluded SNPs
that 1) were not available in at least half of the maximum sample size in each stratum; 2) had a
heterogeneity I2 >75%, or 3) were missing chromosomal and base position annotation in
dbSNP.
Calculation of the significance of SNP×PA interaction and of the joint significance of
SNP main effect and SNP×PA interaction. To identify SNP×PA interactions, we used the
EasyStrata R package [46] to test for the difference in meta-analyzed beta-coefficients between
the active and inactive groups for the association of each SNP with BMI, WCadjBMI and
WHRadjBMI. Easystrata tests for differences in effect estimates between the active and inactive
strata by subtracting one beta from the other (βactive−βinactive,) and dividing by the overall stan-
dard error of the difference as follows:
Zdiff ¼
bactive   binactiveffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SE2active   SE2inactive   2 r  SE2active  SE2inactive
p
where r is the Spearman rank correlation coefficient between βactive and βinactive for all
genome-wide SNPs. The joint significance of the SNP main and SNP×PA interaction effects
was estimated using the method by Aschard et al. [16] which is a joint test for genetic main
effects and gene-environment interaction effects where gene-environment interaction is calcu-
lated as the difference in effect estimates between two exposure strata, accounting for 2 degrees
of freedom.
Testing for secondary signals. Approximate conditional analyses were conducted using
GCTA version 1.24 [19]. In the analyses for SNPs identified in our meta-analyses of European-
ancestry individuals only, LD correlations between SNPs were estimated using a reference
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sample comprised of European-ancestry participants of the Atherosclerosis Risk in Communi-
ties (ARIC) study. In the analyses for SNPs identified in our meta-analyses of all ancestries
combined, the reference sample comprised 93% of European-ancestry individuals and 6% of
African ancestry participants from ARIC, as well as 1% of CHB and JPT samples from the
HapMap2 panel, to approximate the ancestry mixture in our all ancestry meta-analyses. To
test if our identified SNPs were independent secondary signals that fell within 1 Mbp of a pre-
viously established signal, we used the GCTA—cojo-cond command to condition our lead
SNPs on each previously established SNP in the same locus.
Replication analysis for the CDH12 locus. The replication analysis for the CDH12 locus
included participants from the EPIC-Norfolk (NINACTIVE = 4,755, NACTIVE = 11,526) and Fen-
land studies (NINACTIVE = 1,213, NACTIVE = 4,817), and from the random subcohort of the
EPIC-InterAct Consortium (NINACTIVE = 2,154, NACTIVE = 6,632). PA stratum-specific esti-
mates of the association of CDH12 with BMI were assessed and meta-analyzed by fixed effects
meta-analyses, and the differences between the PA-strata were determined as described above.
Examining the influence of BMI, WCadjBMI and WHRadjBMI-associated
loci on other complex traits and their potential functional roles
NHGRI-EBI GWAS catalog lookups. To identify associations of the novel BMI,
WCadjBMI or WHRadjBMI loci with other complex traits in published GWAS, we extracted pre-
viously reported GWAS associations within 500 kb and r2>0.6 with any of the lead SNPs,
from the GWAS Catalog of the National Human Genome Research Institute and European
Bioinformatics Institute [47] (S14 Table).
eQTLs. We examined the cis-associations of the novel BMI, WCadjBMI or WHRadjBMI loci
with the expression of nearby genes from various tissues by performing a look-up in a library
of>100 published expression datasets, as described previously by Zhang et al [48]. In addition,
we examined cis-associations using gene expression data derived from fasting peripheral
whole blood in the Framingham Heart Study [49] (n = 5,206), adjusting for PA, age, age2, sex
and cohort. For each novel locus, we evaluated the association of all transcripts ±1 Mb from
the lead SNP. To minimize the potential for false positives, we only considered associations
where our lead SNP or its proxy (r2>0.8) was either the peak SNP associated with the expres-
sion of a gene transcript in the region, or in strong LD (r2>0.8) with the peak SNP.
Overlap with functional regulatory elements. We used the Uncovering Enrichment
Through Simulation method to combine the genetic association data with the Roadmap Epige-
nomics Project segmentation data [22]. First, 10,000 sets of random SNPs were selected
among HapMap2 SNPs with a MAF >0.05 that matched the original input SNPs based on
proximity to a transcription start site and the number of LD partners (r2>0.8 in individuals of
European ancestry in the 1000 Genomes Project). The LD partners were combined with their
original lead SNPs to create 10,000 sets of matched random SNPs and their respective LD part-
ners. These sets were intersected with the 15-state ChromHMM data from the Roadmap Epi-
genomics Project and resultant co-localizations were collapsed from total SNPs down to loci,
which were then used to calculate an empirical P value when comparing the original SNPs to
the random sets. We examined the enrichment for all loci reaching P<10−5 for SNP×PA inter-
action combined, and for all loci reaching P<5x10-8 in the PA-adjusted SNP main effect
model combined. In addition, we examined the variant-specific overlap with regulatory ele-
ments for each of the index SNPs of the novel BMI, WCadjBMI and WHRadjBMI loci and vari-
ants in strong LD (r2>0.8).
Estimation of variance explained in inactive and active groups. We compared variance
explained for BMI, WCadjBMI and WHRadjBMI between the active and inactive groups using
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two approaches. First, we used a method previously reported by Kutalik et al [15], and selected
subsets of SNPs based on varying P value thresholds (ranging from 5x10-8 to 0.05) from the
SNP main effect model adjusted for PA. Each subset of SNPs was clumped into independent
regions using a physical distance criterion of<500kb, and the most significant lead SNP
within the respective region was selected. For each lead SNP, the explained variance was calcu-
lated as:
r2 ¼
1
1þ N
F  1 P
2ð Þð Þ
2
 
1
N
in the active and inactive groups separately, where N is the sample size and P is the P value for
SNP main effect in active or inactive strata. Finally, the variance explained by each subset of
SNPs in the active and inactive strata was estimated by summing up the variance explained by
the SNPs.
Second, we applied the LD Score regression tool developed by Bulik-Sullivan et al [14] to
quantify the proportion of inflation due to polygenicity (heritability) rather than confounding
(cryptic relatedness or population stratification) using meta-analysis summary results. LD
Score regression leverages LD between causal and index variants to distinguish true signals by
regressing meta-analysis summary results on an ‘LD Score’, i.e. the cumulative genetic varia-
tion that an index SNP tags. To obtain heritability estimates by PA strata, we regressed our
summary results from the genome-wide meta-analyses of BMI, WCadjBMI and WHRadjBMI,
stratified by PA status (active and inactive), on pre-calculated LD Scores available in HapMap3
reference samples of up to 1,061,094 variants with MAF1% and N>10th percentile of the
total sample size.
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